Loading stock data…
Kiniksa Pharmaceuticals Interna (KNSA)
$62.41+3.21 (+5.42%)
After Hours$63.22+0.81 (+1.30%)· Last close Jun 29
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kiniksa Pharmaceuticals International, plc in the Healthcare sector is trading at $62.41 with a market capitalization of $3.7B. Wall Street consensus targets $65.12 (8 analysts), implying a +4.4% move over the next 12 months. The stock is currently near its 52-week high of $63.77, remaining 39.7% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $214.27M↑ | $202.13M↑ | $180.85M↑ | $156.80M↑ | $137.78M |
| Gross Profit | $117.89M↑ | $111.15M↑ | $97.29M↑ | $85.78M↑ | $76.13M |
| Operating Income | $29.27M↑ | $19.77M↓ | $24.02M↑ | $20.16M↑ | $13.27M |
| Net Income | $22.59M↑ | $14.20M↓ | $18.43M↑ | $17.83M↑ | $8.54M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
52.58
Beta
Defensive asset. Lower volatility than the S&P 500.
0.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.06%
Volume
Today's trading volume
1.50M
Recent News
Grab These 4 Stocks With Solid Net Profit Margins to Maximize Returns
Let's take a look at four stocks, BTSG, KNSA, ATI and VMI, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View
Biotech firm Kiniska is a standout with its profitability. The biotech stock is moving toward a buy zone amid a winning streak.
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know
Kiniksa Pharmaceuticals International, plc (KNSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).